An open-label, single-arm Phase II study of intravenous weekly (Days 1 and 8) topotecan in combination with carboplatin (Day 1) every 21 days as second-line therapy in patients with platinum-sensitive relapsed ovarian cancer

✍ Scribed by Peter G. Rose; Bradley J. Monk; Diane Provencher; Jean Hartney; Philippe Legenne; Stephen Lane

• Book ID: 113962651
• Publisher: Elsevier Science
• Year: 2011
• Tongue: English
• Weight: 192 KB
• Volume: 120
• Category: Article
• ISSN: 0090-8258
• DOI: 10.1016/j.ygyno.2010.10.011